Published in Br J Haematol on February 08, 2010
DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle (2013) 0.86
Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability. PLoS One (2015) 0.82
Waldenström's macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders. Blood Cancer J (2012) 0.77
Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms. Sci Rep (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet (2010) 5.04
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet (2009) 4.47
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol (2013) 3.75
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood (2011) 2.69
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood (2006) 2.43
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood (2007) 2.38
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
Optimizing protein stability in vivo. Mol Cell (2009) 2.15
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood (2008) 1.98
Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood (2002) 1.95
The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma (2009) 1.77
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol (2011) 1.71
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol (2011) 1.71
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res (2007) 1.70
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood (2010) 1.67
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol (2011) 1.66
Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J (2011) 1.65
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma. Haematologica (2006) 1.64
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology (2014) 1.64
MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukemia. Blood (2010) 1.62
The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res (2011) 1.61
Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood (2003) 1.60
High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma (2010) 1.58
Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res (2003) 1.53
Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol (2009) 1.48
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood (2008) 1.45
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. Blood (2013) 1.45
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res (2011) 1.44
Self-expanding stent implantation in arterial duct during hybrid palliation of hypoplastic left heart syndrome: midterm experience with a specially designed stent. EuroIntervention (2015) 1.39
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res (2010) 1.39
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood (2010) 1.36
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood (2013) 1.35
Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood (2002) 1.34
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood (2012) 1.33
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica (2011) 1.32
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood (2011) 1.32
Untangling the unfolded protein response. Cell Cycle (2008) 1.32
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol (2009) 1.26
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood (2002) 1.22
Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma. Ther Clin Risk Manag (2006) 1.20
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol (2011) 1.20
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica (2008) 1.20
Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res (2008) 1.19
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem (2002) 1.18
The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res (2003) 1.17
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood (2013) 1.16
Genetic variation in the folate metabolic pathway and risk of childhood leukemia. Blood (2010) 1.14
Epigenetic consequences of AML1-ETO action at the human c-FMS locus. EMBO J (2003) 1.14
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol (2013) 1.13
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood (2007) 1.11
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res (2013) 1.11
Cost-effectiveness of transcatheter aortic valve implantation versus surgery for high-risk patients with aortic stenosis. J Am Coll Cardiol (2013) 1.09